Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Atezolizumab (Primary) ; Paclitaxel
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- 13 Jun 2017 Status changed from active, no longer recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.